Lido Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Lido Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,100	Closed	-$170K	–	1272
2022 Q4	$170K	Sell	16,100 -2,200	-12%	-$17.8K	﹤0.01%	918
2022 Q3	$82K	Hold	18,300	–	–	﹤0.01%	914
2022 Q2	$73K	Hold	18,300	–	–	﹤0.01%	908
2022 Q1	$133K	Hold	18,300	–	–	﹤0.01%	965
2021 Q4	$102K	Hold	18,300	–	–	﹤0.01%	974
2021 Q3	$117K	Hold	18,300	–	–	﹤0.01%	939
2021 Q2	$154K	Hold	18,300	–	–	﹤0.01%	884
2021 Q1	$192K	Sell	18,300 -275	-1%	-$3.87K	﹤0.01%	812
2020 Q4	$314K	Sell	18,575 -1,075	-5%	-$16.1K	0.01%	608
2020 Q3	$252K	Hold	19,650	–	–	0.01%	533
2020 Q2	$277K	Sell	19,650 -1,720	-8%	-$21.7K	0.01%	469
2020 Q1	$197K	Sell	21,370 -17,500	-45%	-$226K	0.01%	522
2019 Q4	$579K	Sell	38,870 -900	-2%	-$8.02K	0.02%	353
2019 Q3	$271K	Buy	39,770 +10,220	+35%	+$103K	0.01%	479
2019 Q2	$357K	Buy	29,550 +2,750	+10%	+$15K	0.02%	382
2019 Q1	$61K	Hold	26,800	–	–	﹤0.01%	515
2018 Q4	$47K	Buy	+26,800	New	+$77K	﹤0.01%	431

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Lido Advisors's PRVB Position: Q1 2023 in Review

Lido Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 16,100 shares — an estimated $170K sold.

Lido Advisors first reported a position in PRVB in Q4 2018 and held it in 17 quarters. The position peaked at $579K in Q4 2019. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

Lido Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Lido Advisors sold 16,100 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $170K.
Lido Advisors first reported a position in Provention Bio, Inc. Common Stock in Q4 2018 and held it in 17 quarters.
Lido Advisors's Provention Bio, Inc. Common Stock position peaked at $579K in Q4 2019.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Lido Advisors's 13F filing for Q1 2023, filed 15 May 2023.